UCLA research on postmortem brains and animal models challenges the single-cause model of narcolepsy with cataplexy.
Key takeaways:
- UCLA Health researchers discovered that narcolepsy with cataplexy involves neuron degeneration in the locus coeruleus, in addition to the previously established loss of orexin/hypocretin neurons in the hypothalamus.
- Postmortem brain analysis showed narcolepsy patients had an average 46% loss of norepinephrine-producing neurons compared to controls, accompanied by signs of neuroinflammation.
- The findings help explain why 15% to 30% of patients with cataplexy have normal orexin levels and why norepinephrine-boosting medications provide meaningful symptom relief.
For nearly 25 years, scientists believed the primary cause of narcolepsy type 1 was solely the loss of hypocretin/orexin neurons in the hypothalamus. A new study suggests that understanding is only part of the picture.
In a study published in Nature Communications, UCLA Health researchers link narcolepsy with cataplexy to the degeneration of neurons in a second critical region of the brainstem: the locus coeruleus. This small cluster of cells produces norepinephrine, a neurotransmitter involved in arousal and the regulation of muscle tone.
“The locus coeruleus has both upward connections that contribute to wakefulness and downward connections that help maintain muscle tone,” says Thomas Thannickal, PhD, associate researcher at the David Geffen School of Medicine at UCLA, in a release. “That makes it a compelling candidate for explaining both of the defining symptoms of narcolepsy (of sleepiness and cataplexy) in a way that the neuronal degeneration in the hypothalamus alone does not fully account for.”
Using postmortem brain tissue from 11 individuals diagnosed with narcolepsy with cataplexy and five neurologically healthy controls, researchers found that every narcolepsy patient showed a substantial loss of neurons in the locus coeruleus. On average, patients had 46% fewer of these norepinephrine-producing neurons compared to controls, with individual losses ranging from 28% to 66%. Notably, the surviving neurons were about 18% larger than normal, suggesting the remaining cells must work harder to compensate for the loss.
The research team also found signs of neuroinflammation. The brain’s immune cells, known as microglial cells, were more than twice as numerous in narcolepsy patients as in controls and were significantly larger. A similar pattern of microglial clustering was observed around orexin neurons in the hypothalamus, pointing toward an immune-mediated process.
To determine whether the locus coeruleus loss was simply a consequence of losing orexin neurons, the researchers examined two mouse models of narcolepsy and narcoleptic dogs. None of these animal models showed a reduction in locus coeruleus neurons, indicating that the brainstem damage observed in human patients is a separate feature of the disease rather than a downstream effect.
The surviving locus coeruleus neurons showed few of the protein deposits typically seen in Parkinson’s or Alzheimer’s disease, suggesting the cell loss in narcolepsy follows a distinct, immune-driven pathway. However, researchers did note some deposits of tau and alpha-synuclein in the locus coeruleus of narcolepsy patients, a finding they note warrants further investigation.
The research adds context to a long-standing puzzle in sleep medicine: between 15% and 30% of patients who meet clinical criteria for narcolepsy with cataplexy have normal orexin levels in their cerebrospinal fluid. The involvement of a second neuronal system may help account for cases that do not fit neatly into the orexin-deficiency model. It also helps explain why drugs that boost norepinephrine activity, such as reboxetine and solriamfetol, produce meaningful symptom relief.
“This doesn’t overturn what we know about hypocretin and narcolepsy,” says Jerome Siegel, PhD, professor-in-residence of psychiatry at the David Geffen School of Medicine at UCLA and director of the Center for Sleep Research at the Semel Institute for Neuroscience and Human Behavior at UCLA, in a release. “But it does suggest we’ve been looking at only part of the picture. Understanding the full scope of the neurological changes in narcolepsy patients is essential if we want to develop more targeted therapies.”
